Navigation Links
Study Examines Media Preferences of Life Scientists in Applied Markets
Date:1/4/2008

ARLINGTON, Va., Jan. 4 /PRNewswire/ -- Faced with modest growth in the traditional life science market, suppliers are turning their attention to opportunities in agricultural, biodefense and molecular diagnostics. To help companies navigate these unfamiliar waters, leading research and advisory firm BioInformatics, LLC today released its latest report examining the marketing and media preferences of scientists working in these dynamic markets. The report, "Marketing to Life Scientists: Capturing Customers' Attention in Applied Markets" highlights the importance of effective marketing in capturing mindshare in markets where product differentiation can be hard to achieve.

A complimentary Executive Summary of the report is available at: http://www.gene2drug.com/reports/default.asp?action=details&report_id=186

"This report can help life science companies determine the right combination of marketing messages and tactics to efficiently reach their target audience in these applied markets," said Tamara Zemlo, PhD, Director of Syndicated Research at BioInformatics, LLC. "Scientists working in these fields share many similarities with those in basic research and drug discovery, but there are also some striking differences that marketers can exploit for optimal effectiveness."

The scientists surveyed also ranked the effectiveness of their suppliers' marketing programs in terms of "best" Web site, print catalog, exhibits, print advertising and sales force. While hundreds of companies were mentioned, market leaders such as Bio-Rad Laboratories (Amex: BIO), BD Biosciences (NYSE: BDX), Invitrogen (Nasdaq: IVGN), Sigma-Aldrich (Nasdaq: SIAL), Thermo Fisher Scientific (NYSE: TMO), and New England Biolabs all received exceptionally high rankings in multiple categories.

"When the data is analyzed by segment, however, it's clear that some firms have been more successful than others in raising awareness of their brands in the agricultural, biodefense and molecular diagnostics markets," observed Zemlo.

Key findings of the report will be shared in a complimentary Webinar presented on January 15, 2008 at 1:00 p.m. ET. To register to attend the Webinar, please email webinars@gene2drug.com.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 35,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

For more information, please contact:

Catherine Seguin

Director of Communications

BioInformatics, LLC

2111 Wilson Blvd., Suite 250

Arlington, VA 22201

703.778.3080 x13 (phone)

c.seguin@gene2drug.com

http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Triage study challenges notions of emergency medical response to disaster
2. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
3. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
4. Study Reaffirms Superiority of Trofile(TM) Assay
5. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
6. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
7. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
8. National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment
9. Berlin Heart Enrolls First Patient in US Multi-Center EXCOR(R) Pediatric VAD IDE Study
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 For today, Stock-Callers.com redirects investors, ... development and clinical research aimed at treating diseases and medical ... Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), ... can access our complimentary research reports on these stocks now ... http://stock-callers.com/registration ...
(Date:4/19/2017)... Philadelphia, PA (PRWEB) , ... April 18, 2017 ... ... name to Halo Labs . The move comes after the company changed ... this new market, our new brand and our new technology,” says CEO Robert ...
(Date:4/19/2017)... Linda, Ca (PRWEB) , ... April 19, 2017 ... ... University Virtual Event, which makes educational webinars accessible to novices as well ... impact of preanalytical variables of commonly performed coagulation screening tests. , Hemostasis ...
(Date:4/19/2017)... , April 19, 2017 Veracyte, ... announced that it will report its first quarter ... May 3, 2017. Following the announcement, Veracyte,s management will host ... Eastern Time to discuss the company,s financial results and ... subsequent replay may be accessed by visiting Veracyte,s website at  ...
Breaking Biology Technology:
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):